| Olivier
Meyer, Ph.D.
President and CEO
Olivier Meyer has a Ph.D. in Pharmaceutical Sciences
from Université de Paris XI, France. Dr.
Meyer subsequently did his postdoctoral fellowship
at the University of California Cancer Research
Institute in San Francisco where he developed various
innovative nano-particulate systems for the targeted
transport of oncology drugs. Dr. Meyer held several
positions in research and development at Transgène
S.A. in Strasbourg, France, before becoming Vice-President,
Research and Development of Bioxalis Medica Inc.,
acquired by Procyon Biopharma Inc. in 2005 and since
renamed Ambrilia Biopharma Inc. Prior to joining
the Bioxel Pharma Inc. team, Dr. Meyer held an executive
position at AstraZeneca R&D Montreal.
|
Stock information
| Symbol |
TSX : BIP |
| Last trade |
0.01 |
| Open |
0.01 |
| Net change |
0.00 |
| High |
0.01 |
| Low |
0.01 |
| 52 week range |
0.01 - 0.25 |
| Volume |
0 |
| As of |
2008-12-03
15:20 EST |
Quotes are delayed. For informational purposes only.
|
